Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
|Articles|August 1, 2002
Combination therapy lowers BPH progression risk by 67%
Orlando, FL-In a finding that will likely change the way physicianstreat patients with benign prostatic hyperplasia, the combination of twocommonly used drugs was shown to slow progression of the disease significantlybetter than placebo or either drug alone. In fact, treatment with the combinationof finasteride (Proscar) and doxazosin (Cardura) lowers the risk of BPHprogression by as much as 67% and the risk of urinary retention by as muchas 79%.
Advertisement
Advertisement
Related to this article
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Advertisement
Advertisement
Trending on Urology Times
1
Matching mCSPC treatment to the patient, not just the trial data
2
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
3
Urocross Expander System enters US commercial use for symptomatic BPH
4
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
5